M344: Potent HDAC Inhibitor (IC50 100 nM) for Cancer and HIV Research

Executive Summary: M344 is a cell-permeable histone deacetylase (HDAC) inhibitor with an IC50 of 100 nM, widely used in epigenetic and cancer research (APExBIO). It induces histone acetylation and suppresses proliferation in breast cancer, medulloblastoma, and neuroblastoma cell lines. M344 enhances radiation sensitivity in squamous carcinoma models and activates HIV-1 LTR gene expression via NF-κB modulation. The compound is soluble in DMSO and ethanol, but not water, and requires careful handling in lab workflows. Efficacy and toxicity profiles are well-documented in vitro and ex vivo models (related benchmark).

Biological Rationale

Histone deacetylases regulate chromatin structure by removing acetyl groups from histone proteins, leading to condensed chromatin and transcriptional repression. In many cancers, aberrant HDAC activity causes epigenetic silencing of tumor suppressor genes. Inhibition of HDACs restores histone acetylation, reopening chromatin and reactivating beneficial gene expression. HDAC inhibitors are established tools for investigating gene regulation, cell cycle control, and induction of apoptosis in cancer cells (see extended review). M344, developed and supplied by APExBIO, is selected for its potency, cell permeability, and robust activity in key disease models.

Mechanism of Action of M344

M344 inhibits HDAC enzymes at nanomolar concentrations (IC50: 100 nM), leading to increased acetylation of histone residues. This change in histone acetylation status alters chromatin architecture, facilitating transcriptional activation or repression of target genes. M344-induced acetylation modulates transcription factors, notably NF-κB, which is implicated in immune response and viral latency control. In cancer models, this mechanism results in cell cycle arrest, induction of apoptosis, and promotion of differentiation. In latency models, M344 reactivates HIV-1 LTR-driven gene expression, highlighting its value in anti-latency strategies (mechanistic insights).

Evidence & Benchmarks

• M344 inhibits HDAC enzymes with an IC50 of 100 nM in cell-free biochemical assays (APExBIO product page).
• Suppresses proliferation in MCF-7 breast cancer, D341 MED medulloblastoma, and CH-LA 90 neuroblastoma cells, with GI50 values of 0.63–0.65 μM (https://www.apexbt.com/m344.html).
• Enhances radiation response in human squamous carcinoma cell lines SCC-35 and SQ-20B, increasing sensitivity to ionizing radiation (benchmarking study).
• Induces cell differentiation at sub-toxic concentrations (1–10 μM); above 10 μM, M344 exhibits marked cytotoxicity (https://www.apexbt.com/m344.html).
• Activates HIV-1 LTR gene expression via NF-κB modulation, supporting use in HIV-1 latency reversal research (mechanism review).
• Demonstrates lower toxicity in ex vivo Wistar rat brain slice cultures compared to SAHA, but with less favorable toxicity profile (https://flaconitineonline.com/index.php?g=Wap&m=Article&a=detail&id=12).
• Solubility: ≥14.75 mg/mL in DMSO, ≥12.88 mg/mL in ethanol with ultrasonic assistance; insoluble in water (https://www.apexbt.com/m344.html).

Applications, Limits & Misconceptions

M344 is routinely used in:

• Cancer biology: To inhibit proliferation and induce apoptosis in cell-based assays (breast cancer, neuroblastoma, medulloblastoma).
• Epigenetic modulation: As a tool for studying histone acetylation and chromatin remodeling.
• HIV-1 research: To activate latent HIV-1 LTR gene expression via NF-κB, supporting 'shock and kill' latency reversal strategies.
• Radiation sensitization: As an adjunct in radiobiology to enhance tumor cell kill.

Compared to other HDAC inhibitors, M344 offers robust cell permeability and potent submicromolar inhibition. However, its toxicity profile in neural tissue, relative to compounds like SAHA, requires careful dose selection (see ex vivo analysis).

Common Pitfalls or Misconceptions

• M344 is not water soluble: Direct dissolution in aqueous buffers leads to precipitation and loss of activity.
• Long-term solution storage is not recommended: M344 solutions degrade over time; prepare fresh solutions for each experiment.
• High concentrations (>10 μM) are cytotoxic: At these levels, cell death increases and differentiation is limited to a surviving fraction.
• Not all cell lines respond equally: Sensitivity varies; optimization is needed for each model system.
• Not a direct comparator to tamoxifen/toremifene: While all affect transcription, M344 acts through epigenetic mechanisms, not ER modulation (Cochrane breast cancer review).

Workflow Integration & Parameters

• Solubility: Dissolve in DMSO (≥14.75 mg/mL) or ethanol (≥12.88 mg/mL with ultrasonic assistance). Warming to 37°C and ultrasonic shaking enhance dissolution (M344 product page).
• Storage: Store solid at -20°C; do not store solutions long term.
• Experimental concentrations: Typical working range is 1–100 μM; treatment durations from 1 to 7 days. Cytotoxicity increases notably above 10 μM.
• Assay compatibility: Suitable for apoptosis, cell cycle, histone acetylation, and gene expression assays (workflow guidance).

This article extends discussion beyond the procedural focus of the workflow guide by integrating mechanistic and benchmarking data for M344.

Conclusion & Outlook

M344, as provided by APExBIO, is a validated, potent HDAC inhibitor, enabling precise control of epigenetic states in cancer and HIV latency models. Its robust activity in diverse cellular systems and compatibility with standard cytometric and molecular assays have established it as a gold-standard research tool. Limitations include solubility and cytotoxicity at higher concentrations, as well as variable sensitivity across cell lines. Future research may refine its application in combinatorial regimens and in vivo models. For further mechanistic depth, readers may consult this mechanistic review, which this article updates with recent toxicological and workflow findings.